[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Prenatal & Maternal Diagnostic Marketplace Analysed in New Kelly Scientific Publications Report Available at MarketPublishers.com

12 Jan 2016 • by Natalie Aster

LONDON – Worldwide, 50 countries have effective newborn genetic test programmes being implemented at all stages. In the USA, 4 million neonates are tested on an annual basis, and close to 3,000 are found to have certain metabolic and genetic diseases. The aim of newborn screening is to quickly identify affected newborn babies and give them medical treatment to prevent mental retardation, prolonged illness and death. The market for newborn genetic screening is overcrowded with diverse technologies, with the most typical common being tandem mass spectrometry (tandem MS), enzyme-based assays, pulse oximetry, electrophoresis and DNA assays. 

Preimplantation genetic screening (PGS) and preimplantation genetic diagnosis (PGD) are genetic tests carried out in 8-cell embryos before implantation during in vitro fertilisation (IVF) to detect sex and genetic abnormalities. These tests can detect and diagnose chromosomal rearrangements, X-linked disorders and assist in decreasing miscarriage rates, increasing implantation rates, preventing trisomic offsprings and avoiding the risk of transmitting single-gene disorders. However, PGD and PGS results are not 100% accurate. In the USA alone, over 63,000 babies were born using IVF in 2013, an upsurge of 2,000 births compared to 2012 data.

One of the most vital developments in the prenatal screening domain was the introduction of non-invasive prenatal tests (NIPTs) using cell-free fetal DNA (cffDNA) in 2011. Obstetricians and patients are willingly embracing NIPTs which have just 0.1% of false positive results.

Within 4 years, molecular genetics companies have successfully produced 8 different kit types used to detect genetic abnormalities in the fetus. If companies can develop NIPTs with a 100% accuracy rate, amniocentesis, chorionic villus sampling (CVS) and maternal serum tests are all likely be fully driven out by NIPTs.

New report “Global Prenatal & Maternal Diagnostic Market To 2020” developed by Kelly Scientific Publications provides an in-depth overview of the various technologies utilised for detecting a variety of genetic disorders in embryos, fetuses and neonates. The study offers an overview of prenatal pregnancy complications; types of genetic diseases in fetuses; genetic counselling; prenatal screening for genetic diseases; newborn screening; PGS and PGD; pregnancy, prenatal, newborn and PGD-related technologies; prenatal screening and diagnostics; other genetic testing related marketplaces. The report offers a SWOT and M&A analysis of the market; evaluates emerging trends in associated markets. It also thoroughly reviews the 114 market players. 

Report Details:

Global Prenatal & Maternal Diagnostic Market To 2020
Published: January, 2016
Pages: 359
Price: US$ 3,800.00 

More studies by the publisher can be found at Kelly Scientific Publications page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected] 


Analytics & News

Weekly Digest